A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

University of Pennsylvania, Philadelphia

Wake Forest University Health Sciences, Winston-Salem

Bon Secours Saint Francis Cancer Center, Greenville

Orlando Health, Inc, Orlando

Vanderbilt Ingram Cancer Center, Nashville

Parkview Cancer Center, Fort Wayne

Karmanos Cancer Institute, Detroit

University of Kansas Cancer Center, Westwood

Tulane University Health Sciences Center, New Orleans

University of Texas Southwestern Medical Center, Dallas

The University of Texas MD Anderson Cancer Center-merge, Houston

University of Southern California, Los Angeles

Pacific Shores Medical Group, Long Beach

City of Hope National Medical Center, Duarte

University of California San Diego, San Diego

Local Institution, Palo Alto

UC Davis Comprehensive Cancer Center, Sacramento

Local Institution, Sendai

UCLA Clinical and Translational Research Center (CTRC), Los Angeles

Hartford Healthcare Cancer Institute at the Hospital of Central Connecticut, Plainville

Dana Farber/Harvard Cancer Center, Boston

Local Institution, San Juan